Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Fennec Pharmaceuticals (FENC) over the last 11 years, with Q3 2025 value amounting to $50000.0.

  • Fennec Pharmaceuticals' Gains from Investment Securities rose 156666.67% to $50000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $170000.0, marking a year-over-year increase of 14285.71%. This contributed to the annual value of $176000.0 for FY2024, which is 12564.1% up from last year.
  • Fennec Pharmaceuticals' Gains from Investment Securities amounted to $50000.0 in Q3 2025, which was up 156666.67% from $99000.0 recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Gains from Investment Securities peaked at $5.2 million during Q2 2024, and registered a low of $3000.0 during Q3 2024.
  • For the 5-year period, Fennec Pharmaceuticals' Gains from Investment Securities averaged around $2.1 million, with its median value being $1.5 million (2021).
  • In the last 5 years, Fennec Pharmaceuticals' Gains from Investment Securities crashed by 9970.89% in 2023 and then surged by 156666.67% in 2025.
  • Fennec Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $3.7 million in 2021, then crashed by 99.23% to $28000.0 in 2022, then increased by 25.0% to $35000.0 in 2023, then tumbled by 74.29% to $9000.0 in 2024, then soared by 455.56% to $50000.0 in 2025.
  • Its Gains from Investment Securities stands at $50000.0 for Q3 2025, versus $99000.0 for Q2 2025 and $12000.0 for Q1 2025.